Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dale Porter

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer Research|December 20, 2007
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signalingAlex Gaither, Dale Porter, Yao Yao, et al.
Environmental Health Perspectives|May 8, 2013
Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS Nano GO ConsortiumJames C Bonner, Rona M Silva, Alexia J Taylor, et al.
Cancer Research|September 24, 2016
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer CellsThomas Horn, Stéphane Ferretti, Nicolas Ebel, et al.
BMC Cancer|April 17, 2015
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signalingJasna Bancovik, Dayson F Moreira, Daniel Carrasco, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2003
A neural survival factor is a candidate oncogene in breast cancerDale Porter, Stanislawa Weremowicz, Koei Chin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactionsB Barry Touré, Karen Miller-Moslin, Naeem Yusuff, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2013
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionRizwan Haq, Satoru Yokoyama, Elena B Hawryluk, et al.
Journal of Medicinal Chemistry|August 3, 2021
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor InteractionDavid C McKinney, Brian J McMillan, Matthew J Ranaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Molecular Cell|August 6, 2021
Molecular basis for substrate recruitment to the PRMT5 methylosomeKathleen M Mulvaney, Christa Blomquist, Nischal Acharya, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer Research|December 20, 2007
A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signalingAlex Gaither, Dale Porter, Yao Yao, et al.
Environmental Health Perspectives|May 8, 2013
Interlaboratory evaluation of rodent pulmonary responses to engineered nanomaterials: the NIEHS Nano GO ConsortiumJames C Bonner, Rona M Silva, Alexia J Taylor, et al.
Cancer Research|September 24, 2016
High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer CellsThomas Horn, Stéphane Ferretti, Nicolas Ebel, et al.
BMC Cancer|April 17, 2015
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signalingJasna Bancovik, Dayson F Moreira, Daniel Carrasco, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2003
A neural survival factor is a candidate oncogene in breast cancerDale Porter, Stanislawa Weremowicz, Koei Chin, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
The role of the acidity of N-heteroaryl sulfonamides as inhibitors of bcl-2 family protein-protein interactionsB Barry Touré, Karen Miller-Moslin, Naeem Yusuff, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2013
BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionRizwan Haq, Satoru Yokoyama, Elena B Hawryluk, et al.
Journal of Medicinal Chemistry|August 3, 2021
Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor InteractionDavid C McKinney, Brian J McMillan, Matthew J Ranaghan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion StudyLucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, et al.
Molecular Cell|August 6, 2021
Molecular basis for substrate recruitment to the PRMT5 methylosomeKathleen M Mulvaney, Christa Blomquist, Nischal Acharya, et al.
Pageof 4